Pfizer’s abrupt withdrawal of Oxbryta, a drug for sickle cell disease, has sent shockwaves through the medical community.

After Pfizer withdrew its sickle cell drug from the market, patients with the condition and their doctors were left ...

The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...

Pfizer is withdrawing all of its sickle cell disease drug, Oxbryta, worldwide because of safety concerns. Pfizer ( PFE) ...

The company said it was withdrawing Oxbryta, a daily pill for patients with the disease, a serious, lifelong condition.

U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where ...

The company said benefits no longer outweighed the risks, with data suggesting the drug might increase the risk of pain ...

Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...

Pfizer has announced the withdrawal of all lots of OXBRYTA approved for treating sickle cell disease (SCD) from worldwide ...

Pfizer will voluntarily pull its sickle cell disease (SCD) drug Oxbryta from all markets worldwide, a major blow to a $5.4 ...

Pfizer is pulling its sickle cell disease (SCD) treatment voxelotor (Oxbryta) from global markets after data review showed an ...

Based on new safety signals, Pfizer on Wednesday announced that Oxbryta’s overall benefit “no longer outweighs the risk” in ...